바이오분야 산업화 촉진을 위한 중장기 전략 및 세부 추진방안 연구
| 사업명 | 바이오분야 산업화 촉진 중장기 전략 및 세부 추진방안 |
|---|---|
| 주관연구기관 | 지식경제부 /한국바이오협회 |
| 발행년 | 2010 |
| 키워드 | 산업경쟁력기반구축 |
| 관련링크 | http://www.prism.go.kr/homepage/theme/re...uLevel=110 |
바이오분야 산업화 촉진을 위한 중장기 전략 및 세부 추진방안 연구
과업내용
1. 바이오산업의 개념 및 특성, 정의
2. 국내외 바이오산업 현황
3. 주요국 바이오산업 육성 정책
4. 국내 바이오산업 문제점 분석
5. 바이오 산업화 촉진 중장기 전략"
1. 바이오산업의 개념 및 특성, 정의
2. 국내외 바이오산업 현황
3. 주요국 바이오산업 육성 정책
4. 국내 바이오산업 문제점 분석
5. 바이오 산업화 촉진 중장기 전략"
제1장 서 론 ··········································································································13
제1절 연구의 필요성 및 목적 ···················································································13
1.연구 필요성 ···························································································································13
2.연구 목적 ·······························································································································15
제2절 연구의 내용 및 범위 ·······················································································17
1.연구 내용 ·······························································································································17
2.연구 범위 ·······························································································································17
제2장 국내외 바이오산업 현황 및 전망 ························································19
제1절 전반적인 바이오산업 현황 및 전망 ····························································19
1.세계 헬스케어산업(제약․바이오․생명과학)································································19
2.세계 바이오산업 ···················································································································22
3.아시아(태평양)바이오산업 ································································································27
4.국내 바이오산업 ···················································································································36
제2절 의약바이오 ··········································································································51
1.정의 및 범위 ·························································································································51
2.국내외 시장 현황 및 전망 ·································································································55
제3절 융합바이오/의료기기 ························································································82
1.정의 및 범위 ·························································································································82
2.국내외 시장 현황 및 전망 ·································································································84
제4절 산업바이오 ··········································································································96
1.정의 및 범위 ·························································································································96
2.국내외 시장 현황 및 전망 ·································································································99
제5절 그린바이오 ········································································································114
1.정의 및 범위 ·······················································································································114
2.국내외 시장 현황 및 전망 ·······························································································119
제3장 주요국 바이오산업 육성 정책 ····························································132
제1절 선진국 ················································································································132
1.미국 ·······································································································································132
2.유럽 ·······································································································································155
3.일본 ·······································································································································167
제2절 아시아 주요국가 ·····························································································181
1.중국 ·······································································································································181
2.인도 ·······································································································································201
3.말레이시아 ···························································································································213
4.싱가포르 ·······························································································································233
5.인도네시아 ···························································································································262
제4장 국내 바이오산업 문제점 ······································································274
제1절 전반적인 문제점 ·····························································································274
1.산업 규모 및 구조 ·············································································································274
2.기술 수준 ·····························································································································275
제2절 분야별 현황 및 문제점 ·················································································276
1.의약바이오 ···························································································································276
2.융합바이오/의료기기 ········································································································300
3.산업바이오 ···························································································································312
4.그린바이오 ···························································································································323
제3절 산업체 설문조사 결과 ···················································································336
1.조사 개요 ·····························································································································336
2.조사 결과 ·····························································································································337
3.결과 종합 ·····························································································································359
제5장 중장기 전략 ·····························································································363
제1절 비전 및 목표 ····································································································363
1.의약바이오 ···························································································································363
2.융합바이오/의료기기 ········································································································366
3.산업바이오 ···························································································································368
4.그린바이오 ···························································································································371
제2절 추진전략 및 추진방안 ···················································································377
1.의약바이오 ···························································································································377
2.융합바이오/의료기기 ········································································································392
3.산업바이오 ···························································································································396
4.그린바이오 ···························································································································447
- 첨부파일
- PDF N1404_바이오산업중장기전략보고서(최종).pdf (10.58MB / 다운로드 0)
